Key facts
- Altesa BioSciences presented new Phase 2 study results for vapendavir.
- The presentation occurred at the 2026 American Society for Microbiology (ASM) Microbe Conference.
- The study results reinforce the therapeutic potential of vapendavir.
- Vapendavir is being studied as a targeted approach to preventing rhinovirus-driven COPD exacerbations.
Altesa BioSciences, a clinical-stage pharmaceutical company, presented new findings from a Phase 2 challenge study of its drug candidate, vapendavir, at the 2026 American Society for Microbiology (ASM) Microbe Conference. The clinical findings presented are intended to further reinforce the therapeutic potential of vapendavir. The drug is being investigated as a targeted approach to prevent exacerbations of Chronic Obstructive Pulmonary Disease (COPD) that are driven by rhinovirus infections.